About Us
Our Mission is to improve the patient experience at each stage of their illness with accurate, non-invasive diagnostic and therapy monitoring tools.
Hessian Labs is developing a proprietary methodology for early, accurate, non-invasive diagnosis and monitoring of cancers and other diseases.
Product Platform:
We have developed a novel molecular diagnostics tool based on platelet sequestered proteomic panels. Our HessMaps™ are a robust, reliable assay that definitely indicates disease state and status without being invasive. We plan to launch disease specific HessMaps™ for Clinical applications and as a Companion Diagnostic (CDx) tool for Pharmaceutical Companies with new and existing therapies. Our Focus: cancers and other difficult diseases.
Our Fundamentals
At Hessian Labs, we harness information from platelets, a highly responsive biological system, to build non-invasive tools with ‘next level’ diagnostic capability and certainty.
We believe
Improving patient care starts with an accurate diagnosis.
Diagnostic tools should match science’s evolving understanding of biology.
The most difficult diseases are those that hijack normal physiological processes, as such, we need tools which capture and account for that complexity.
Diagnostic certainty, early and without invasion is here.
Why Platelets?
Platelets sequester disease specific proteins.
Sequestration occurs very early in disease formation.
Sequestration is dynamic, reflecting disease progression or regression.
Our Team
Management
Co-Founder, Chief Executive Officer, Director
Co-Founder, Chief Science Officer, Chair of Scientific Advisory Board
Co-Founder, Senior Scientist, Director
Board of Directors
Co-Founder, CEO, Director
Co-Founder, Director
Director
Director
Scientific Advisory Board
Co-Founder, Chief Science Officer, Chair of Scientific Advisory Board
